There are still too many unknowns about the pipeline to suggest there is further value here.
Buyer views target's diabetes and heartburn treatments as complementary to its drug lineup.
Trade-Ideas LLC identified Santarus (SNTS) as a pre-market mover with heavy volume candidate
Salix Pharmaceuticals announced it will acquire Santarus in a deal worth $2.6 billion.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.